B Group, Inc. 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
B Group, Inc. disclosed 18 US equity positions worth $163.6m in its Q4 2024 13F filing. The largest position was INVESCO QQQ TR at 34.4% of the reported book, followed by ADMA and INSM.
What did B Group, Inc. own in Q4 2024? Top 18 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | INVESCO QQQ TR | 34.4% | $56.2m | 110,000 | – | ||
| 2 | ADMA ADMA BIOLOGICS INC | Healthcare | 24.0% | $39.2m | 2,287,542 | – | |
| 3 | INSM INSMED INC | Healthcare | 14.8% | $24.2m | 350,000 | – | |
| 4 | ZLAB ZAI LAB LTD | Healthcare | 6.4% | $10.5m | 400,000 | – | |
| 5 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 4.5% | $7.3m | 992,000 | – | |
| 6 | AKERO THERAPEUTICS INC | 4.4% | $7.2m | 260,000 | – | ||
| 7 | CLLS CELLECTIS S A | 3.4% | $5.5m | 3,081,501 | – | ||
| 8 | AURA AURA BIOSCIENCES INC | 2.4% | $3.9m | 472,576 | – | ||
| 9 | SGHT SIGHT SCIENCES INC | 1.4% | $2.3m | 629,370 | – | ||
| 10 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 1.0% | $1.7m | 965,556 | – | |
| 11 | ULTRAGENYX PHARMACEUTICAL IN | 0.8% | $1.2m | 29,500 | – | ||
| 12 | SYRE SPYRE THERAPEUTICS INC | 0.7% | $1.2m | 50,000 | – | ||
| 13 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 0.5% | $799.3k | 50,651 | – | |
| 14 | APGE APOGEE THERAPEUTICS INC | Healthcare | 0.4% | $679.5k | 15,000 | – | |
| 15 | CORVUS PHARMACEUTICALS INC | 0.3% | $535.0k | 100,000 | – | ||
| 16 | BNTX BIONTECH SE | Healthcare | 0.2% | $398.8k | 3,500 | – | |
| 17 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.2% | $387.8k | 20,000 | – | |
| 18 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 0.2% | $319.6k | 7,596 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.